MCID: LKM061
MIFTS: 81

Leukemia, Acute Myeloid

Categories: Genetic diseases, Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 53 37
Acute Myeloid Leukemia 37 12 72 49 71 36 28 40 14
Acute Undifferentiated Leukemia 55 51 69
Leukemia, Acute Myelogenous 53 71 13
Acute Myeloblastic Leukemia 12 72 71
Acute Myelogenous Leukemia 12 72 49
Leukemia, Acute Myeloid, Susceptibility to 53 28
Acute Biphenotypic Leukemia 55 69
Leukemia, Myelocytic, Acute 12 69
Acute Myelocytic Leukemia 72 71
Aml 53 71
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 55
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 53
Acute Myeloid Leukemia with Cebpa Somatic Mutations 55
Acute Myeloid Leukemia with Multilineage Dysplasia 55
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 53
Aml with Myelodysplasia-Related Features 55
Pure Familial Acute Myeloid Leukemia 55
Leukemia, Acute Myeloid, Somatic 53
Aml with Cebpa Somatic Mutations 55
Inherited Acute Myeloid Leukemia 55
Acute Non-Lymphoblastic Leukemia 71
Aml with Multilineage Dysplasia 55
Acute Non-Lymphocytic Leukemia 71
Aml - Acute Myeloid Leukemia 12
Leukemia, Myeloid, Acute 41
Bilineal Acute Leukemia 55
Pure Familial Aml 55
Inherited Aml 55
Familial Aml 55

Characteristics:

Orphanet epidemiological data:

55

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
leukemia, acute myeloid:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 601626
Disease Ontology 12 DOID:9119
ICD9CM 34 205.0
MeSH 41 D015470
NCIt 46 C27753 C3171
ICD10 via Orphanet 33 C92.0 C92.8 C95.0
UMLS via Orphanet 70 C1292773 C0023464 C0856823 more
MESH via Orphanet 42 D015456
KEGG 36 H00003
SNOMED-CT via HPO 65 263681008

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 40 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute myeloblastic leukemia without maturation and acute myeloblastic leukemia with maturation, and has symptoms including acute myeloid leukemia, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT/Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Leukine and Lynparza have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are cellular and homeostasis/metabolism

UniProtKB/Swiss-Prot : 71 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

NIH Rare Diseases : 49 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy. Last updated: 10/29/2015

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

Wikipedia : 72 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia without maturation 35.3 FLT3 NPM1
2 acute myeloblastic leukemia with maturation 35.2 FLT3 KIT NPM1
3 platelet disorder, familial, with associated myeloid malignancy 34.3 ETV6 RUNX1
4 leukemia 33.9 CEBPA ETV6 FLT3 JAK2 KIT NPM1
5 acute leukemia 33.5 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
6 cytogenetically normal acute myeloid leukemia 33.4 CEBPA FLT3 IDH1 IDH2 NPM1
7 myeloid leukemia 32.7 CEBPA ETV6 FLT3 GATA2 KIT NPM1
8 myelodysplastic syndrome 31.3 ETV6 FLT3 GATA2 JAK2 KIT KRAS
9 precursor t-cell acute lymphoblastic leukemia 31.1 ETV6 FLT3 MLLT10 NUP214 PICALM
10 lymphoblastic leukemia 31.1 ETV6 FLT3 JAK2 PICALM RUNX1
11 myeloid sarcoma 30.9 FLT3 KIT NPM1
12 acute promyelocytic leukemia 30.9 CEBPA FLT3 NPM1 RUNX1
13 acute non lymphoblastic leukemia 12.5
14 acute biphenotypic leukemia 12.4
15 aml with myelodysplasia-related features 11.9
16 acute leukemia of ambiguous lineage 11.4
17 hematologic cancer 11.2 ETV6 FLT3 GATA2 JAK2 KIT MLLT10
18 erythroleukemia, familial 11.2
19 megakaryocytic leukemia 11.1
20 core binding factor acute myeloid leukemia 11.1 CEBPA FLT3 JAK2 KIT KRAS RUNX1
21 medulloblastoma 11.1
22 chronic myelomonocytic leukemia 11.1 DNMT3A ETV6 FLT3 JAK2 KIT RUNX1
23 leukemia, chronic myeloid 11.1 ETV6 FLT3 GATA2 JAK2 KIT RUNX1
24 leukemia, acute lymphoblastic 11.1 ETV6 FLT3 GATA2 PICALM RUNX1
25 bone marrow cancer 11.0 ETV6 FLT3 JAK2 KIT RUNX1
26 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.0 CEBPA FLT3 KIT RUNX1
27 juvenile myelomonocytic leukemia 11.0 DNMT3A FLT3 JAK2 KRAS RUNX1
28 wilms tumor 1 11.0 CEBPA FLT3 KRAS NPM1 TERT
29 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 11.0 ETV6 FLT3 KIT RUNX1
30 myelofibrosis 11.0 FLT3 IDH1 IDH2 JAK2 KIT
31 undifferentiated pleomorphic sarcoma 11.0 IDH1 IDH2 KIT KRAS
32 aleukemic leukemia cutis 11.0 FLT3 NPM1 RUNX1
33 8p11 myeloproliferative syndrome 11.0 FLT3 KIT RUNX1
34 acute lymphoblastic leukemia, childhood 10.9 ETV6 FLT3 RUNX1
35 bile duct adenocarcinoma 10.9 IDH1 IDH2 KRAS
36 leukemia, acute lymphoblastic 3 10.9 ETV6 FLT3 RUNX1
37 interval angle-closure glaucoma 10.9 IDH1 IDH2
38 intrahepatic cholangiocarcinoma 10.9 IDH1 IDH2 KRAS
39 adult oligodendroglioma 10.9 IDH1 IDH2
40 enchondroma 10.9 IDH1 IDH2
41 cell type cancer 10.8 IDH1 KIT KRAS
42 intracranial chondrosarcoma 10.8 IDH1 IDH2
43 glioma susceptibility 1 10.8 IDH1 IDH2
44 anaplastic oligodendroglioma 10.8 IDH1 IDH2
45 chondroblastic osteosarcoma 10.8 IDH1 IDH2
46 mn1 10.7 ETV6 FLT3
47 intraductal papilloma 10.7 IDH1 IDH2
48 aggressive digital papillary adenocarcinoma 10.7 KIT KRAS
49 multiple enchondromatosis, maffucci type 10.6 IDH1 IDH2
50 lymphoid leukemia 10.4 ETV6 RUNX1

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

53
Heme:
familial acute myelogenous leukemia (aml)

Misc:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations


Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

31
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 31 HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 KRAS LPP NPM1 NUP214 PICALM RUNX1
2 homeostasis/metabolism MP:0005376 10.35 CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
3 hematopoietic system MP:0005397 10.34 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
4 growth/size/body region MP:0005378 10.32 DNMT3A ETV6 FLT3 GATA2 IDH1 JAK2
5 mortality/aging MP:0010768 10.3 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
6 immune system MP:0005387 10.27 JAK2 KIT KRAS NPM1 PICALM RUNX1
7 endocrine/exocrine gland MP:0005379 10.26 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
8 embryo MP:0005380 10.24 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
9 integument MP:0010771 10.09 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
10 neoplasm MP:0002006 10.02 IDH2 JAK2 KIT KRAS NPM1 RUNX1
11 liver/biliary system MP:0005370 10.01 CEBPA GATA2 JAK2 KIT KRAS NPM1
12 no phenotypic analysis MP:0003012 9.86 CEBPA DNMT3A ETV6 FLT3 KIT KRAS
13 normal MP:0002873 9.76 GATA2 JAK2 KIT KRAS RUNX1 TERT
14 reproductive system MP:0005389 9.61 CEBPA CHIC2 DNMT3A GATA2 JAK2 KIT
15 skeleton MP:0005390 9.28 FLT3 IDH1 JAK2 KIT KRAS NSD3

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Leukine 17 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
2
Lynparza 17 45 OLAPARIB AstraZeneca December 2014
3
Mylotarg 17 45 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
4
Neupogen 17 45 FILGRASTIM Amgen Approval April 1998

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 641)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
3
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
5
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 320-67-2 9444
6
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
7
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
8
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
9
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1 33419-42-0 36462
10
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
11
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
12
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
13
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51-45-6, 75614-87-8 774
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
17 Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
18
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
19
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
20
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
22
Nicotine Approved Phase 4 54-11-5 89594 942
23
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
24
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 10883523 5280795 6221
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
26
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
27 Molgramostim Investigational Phase 4,Phase 3 99283-10-0
28
Aclarubicin Investigational Phase 4,Phase 2,Phase 1 57576-44-0 451415
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1
40 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1
41 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1
42 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
44
Histamine Phosphate Phase 4,Phase 3,Phase 1,Phase 2 51-74-1 65513
45 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 2415)

# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
7 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
8 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
9 Treatment of Acute Myeloblastic Leukemia in Younger Patients Completed NCT00390715 Phase 4 chemotherapy
10 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
11 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
12 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
13 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
14 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
15 Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care Completed NCT00161668 Phase 4 Mylotarg
16 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
17 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
18 A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome Completed NCT01041846 Phase 4 No intervention
19 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
21 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
22 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
23 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
24 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4 Interferon-alpha
25 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
26 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
27 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
28 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Active, not recruiting NCT01819792 Phase 4
29 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
30 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Active, not recruiting NCT01200355 Phase 4 micafungin;posaconazole
31 A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
32 King's Invasive Aspergillosis Study II Not yet recruiting NCT02875743 Phase 4 Posaconazole
33 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
34 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Not yet recruiting NCT03176849 Phase 4
35 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
36 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
37 A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Unknown status NCT01303796 Phase 3 Sapacitabine and decitabine;Decitabine
38 Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Unknown status NCT02244658 Phase 3 rhTPO
39 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
40 Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
41 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
42 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
43 Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
44 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
45 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
46 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
47 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
48 Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia Unknown status NCT02072811 Phase 3 DAC;CLAG;Consolidation, I HAM cycle;II Consolidation HiDAraC;Consolidation, III HiDAraC cycle
49 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
50 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 28 CEBPA KRAS
2 Leukemia, Acute Myeloid, Susceptibility to 28

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

38
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 3859)
# Title Authors Year
1
A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. ( 29437791 )
2018
2
High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia. ( 29032147 )
2018
3
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
4
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
5
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
6
Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series. ( 29407318 )
2018
7
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B cell Lymphoma and Acute Myeloid Leukemia: A Report of Two Cases. ( 29321428 )
2018
8
Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning. ( 29416633 )
2018
9
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. ( 29437468 )
2018
10
No Mutation Left Behind: The Impact of Reporting Recurrent Genetic Abnormalities on Outcomes of Patients with Acute Myeloid Leukemia. ( 29444505 )
2018
11
Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. ( 29428448 )
2018
12
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
13
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. ( 29435331 )
2018
14
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. ( 29449224 )
2018
15
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
16
Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. ( 29343975 )
2018
17
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. ( 28960408 )
2018
18
A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia. ( 29439669 )
2018
19
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
20
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. ( 29080220 )
2018
21
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. ( 29448058 )
2018
22
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
23
Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients. ( 29330206 )
2018
24
HLA-Matched Sibling Vs. Unrelated Vs. Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: a Single-Center Donor Comparison. ( 29448057 )
2018
25
Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. ( 29407184 )
2018
26
Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. ( 29451695 )
2018
27
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
28
Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. ( 27819671 )
2017
29
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. ( 28031480 )
2017
30
Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4. ( 27636548 )
2017
31
Decreased miR-144 expression as a non-invasive biomarker for acute myeloid leukemia patients. ( 29441994 )
2017
32
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. ( 28191887 )
2017
33
The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells. ( 28045930 )
2017
34
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. ( 28407515 )
2017
35
CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. ( 28097942 )
2017
36
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences. ( 29180669 )
2017
37
Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22(phox)-derived reactive oxygen species in acute myeloid leukemia. ( 27870947 )
2017
38
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? ( 27915304 )
2017
39
Advances in immunotherapy for pediatric acute myeloid leukemia. ( 28945115 )
2017
40
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. ( 28076884 )
2017
41
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. ( 29071049 )
2017
42
MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. ( 28114278 )
2017
43
Outcome and Minimal Residual Disease Monitoring in t(16;21) Acute Myeloid Leukemia Patients Receiving Allogeneic Hematologic Stem Cell Transplantation. ( 28939454 )
2017
44
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. ( 28644774 )
2017
45
Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia. ( 28992762 )
2017
46
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. ( 28370403 )
2017
47
<i>KRAS</i> overexpression independent of<i>RAS</i>mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. ( 29029494 )
2017
48
Mycobacterium kansasii Pneumonia with Mediastinal Lymphadenitis in a Patient with Acute Myeloid Leukemia: Successful Treatment to Stem Cell Transplantation. ( 28271647 )
2017
49
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. ( 28088653 )
2017
50
A Rare Case of ETV6/MECOM Rearrangement in Therapy-Related Acute Myeloid Leukemia with t(3;12) and Monosomy 7. ( 28182364 )
2017

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

71
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 206)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh37 Chromosome 12, 11992136: 11992136
2 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh37 Chromosome 12, 12043928: 12043929
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
5 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
6 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
7 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
8 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
9 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh38 Chromosome 12, 25245356: 25245358
10 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
13 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
14 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
15 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
17 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
18 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
19 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
20 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
21 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh38 Chromosome 5, 171410540: 171410543
22 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
23 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
24 NPM1 NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
25 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
26 JAK2 NM_004972.3(JAK2): c.1821G> C (p.Lys607Asn) single nucleotide variant Pathogenic rs121912472 GRCh37 Chromosome 9, 5073742: 5073742
27 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913502 GRCh37 Chromosome 15, 90631934: 90631934
28 FLT3 NM_004119.2(FLT3): c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer) insertion Pathogenic rs398122514 GRCh37 Chromosome 13, 28592624: 28592625
29 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
30 FLT3 NM_004119.2(FLT3): c.2503G> C (p.Asp835His) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
31 FLT3 NM_004119.2(FLT3): c.2503G> A (p.Asp835Asn) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
32 FLT3 FLT3, ASP835GLU undetermined variant Pathogenic
33 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
34 FLT3 NM_004119.2(FLT3): c.2503_2505delGAT (p.Asp835del) deletion Pathogenic/Likely pathogenic rs121913486 GRCh37 Chromosome 13, 28592640: 28592642
35 CEBPA NM_004364.4(CEBPA): c.115_121delCCCGCGC (p.Pro39Serfs) deletion Pathogenic rs587776848 GRCh38 Chromosome 19, 33302294: 33302300
36 CEBPA NM_004364.4(CEBPA): c.148G> T (p.Glu50Ter) single nucleotide variant Pathogenic rs121912791 GRCh37 Chromosome 19, 33793173: 33793173
37 CEBPA NM_004364.4(CEBPA): c.251A> T (p.His84Leu) single nucleotide variant Pathogenic rs28931590 GRCh37 Chromosome 19, 33793070: 33793070
38 CEBPA NM_004364.4(CEBPA) duplication Pathogenic GRCh38 Chromosome 19, 33301424: 33301480
39 CEBPA NM_004364.4(CEBPA) duplication Pathogenic GRCh38 Chromosome 19, 33301464: 33301490
40 CEBPA NM_004364.4(CEBPA): c.211_214dupGCCG (p.Ala72Glyfs) duplication Pathogenic rs587776849 GRCh38 Chromosome 19, 33302201: 33302204
41 CEBPA NM_004364.4(CEBPA): c.68delC (p.Pro23Argfs) deletion Pathogenic rs137852728 GRCh38 Chromosome 19, 33302347: 33302347
42 CEBPA NM_004364.4(CEBPA): c.141delC (p.Ala48Profs) deletion Pathogenic rs137852730 GRCh37 Chromosome 19, 33793180: 33793180
43 CEBPA NM_004364.4(CEBPA): c.198_201dupCTAC (p.Ile68Leufs*41) duplication Pathogenic rs137852731 GRCh37 Chromosome 19, 33793120: 33793123
44 CEBPA NM_004364.4(CEBPA): c.217_218insC (p.Phe73Serfs) insertion Pathogenic rs137852733 GRCh37 Chromosome 19, 33793103: 33793104
45 CEBPA NM_004364.4(CEBPA): c.318_319dupTG (p.Asp107Valfs*54) duplication Pathogenic rs137852732 GRCh37 Chromosome 19, 33793002: 33793003
46 CEBPA NM_004364.4(CEBPA): c.68dupC (p.His24Alafs) duplication Pathogenic rs137852729 GRCh37 Chromosome 19, 33793253: 33793253
47 GATA2 NM_032638.4(GATA2): c.1192C> T (p.Arg398Trp) single nucleotide variant Pathogenic/Likely pathogenic rs387906629 GRCh37 Chromosome 3, 128200113: 128200113
48 GATA2 NM_001145661.1(GATA2): c.1061C> T (p.Thr354Met) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs387906631 GRCh37 Chromosome 3, 128200744: 128200744
49 TGM6 NM_198994.2(TGM6): c.1550T> G (p.Leu517Trp) single nucleotide variant Pathogenic rs387907097 GRCh37 Chromosome 20, 2398091: 2398091
50 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

36
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.96 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 cytosol GO:0005829 9.77 ETV6 FLT3 IDH1 IDH2 JAK2 KRAS
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214
4 nucleus GO:0005634 10 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 FLT3 JAK2 KIT KRAS NPM1
2 mitochondrion organization GO:0007005 9.67 CEBPA IDH2 TERT
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 FLT3 JAK2 KIT
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 FLT3 JAK2 KIT
5 2-oxoglutarate metabolic process GO:0006103 9.54 IDH1 IDH2
6 positive regulation of MAP kinase activity GO:0043406 9.54 FLT3 KIT KRAS
7 positive regulation of nitric-oxide synthase activity GO:0051000 9.52 KRAS TERT
8 hematopoietic stem cell proliferation GO:0071425 9.48 ETV6 RUNX1
9 negative regulation of glial cell proliferation GO:0060253 9.46 IDH2 TERT
10 cytokine-mediated signaling pathway GO:0019221 9.35 CEBPA FLT3 JAK2 KIT KRAS
11 myeloid progenitor cell differentiation GO:0002318 9.32 FLT3 KIT
12 isocitrate metabolic process GO:0006102 9.26 IDH1 IDH2
13 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
14 hemopoiesis GO:0030097 9.02 FLT3 GATA2 KIT PICALM RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.73 CEBPA FLT3 IDH1 KIT NPM1 TERT
2 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
3 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH1 IDH2
4 protein binding GO:0005515 10.09 CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
5 metal ion binding GO:0046872 10.06 DNMT3A GATA2 IDH1 IDH2 JAK2 KIT

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....